Vaccination figures now available by municipality RIVM is providing access to COVID-19 vaccination figures by municipality via open data as of today. The open data now includes vaccination turnout and coverage by municipality for three age groups.
New international project Inno4Vac targets faster vaccine development Inno4vac, a new European interdisciplinary project was launched on 1 September. Inno4vac focuses on the design and application of new and highly advanced predictive models to allow a faster development and manufacturing of new vaccines.
Vaccines very effective against hospital and ICU admissions, also for Delta variant COVID-19 vaccines work well in preventing people from being admitted to hospital or ICU for COVID-19, according to a new analysis by RIVM.
COVID-19 vaccination reduces transmission Vaccination against COVID-19 reduces the transmission of the virus from one person to another. This is apparent from RIVM research using data from source and contact tracing by the Municipal Public Health Services (GGDs).
Nearly 85% of people aged 18 and over have had at least one vaccination The RIVM vaccination update this week has been expanded to include three maps of the Netherlands. For the first time, it is now possible to see vaccination turnout by municipality for everyone aged 18 years and over.
Vaccination turnout for people aged 25-44: 66% vaccinated at least once The 26th RIVM vaccination update now shows vaccination turnout for people aged 25-44 years by municipality. This involves people who have received at least one COVID-19 vaccination.
More attention needs to be paid to the safe recycling of waste According to the National Institute for Public Health and the Environment (RIVM) there needs to be a greater (international) focus on, and increased awareness of, the safe recycling of waste.
Heterologous vaccination from 16 July on Following an advisory report by the Health Council, Minister De Jonge decided on 6 July 2021, effective as of 16 July, that people who had received one vaccination with AstraZeneca could opt for the Pfizer/BioNTech for their second jab.
Vaccination coverage is rising, while data is increasingly comprehensive The RIVM vaccination update this week has been expanded to include vaccination coverage by municipality, specifying full COVID-19 vaccination among people aged 65 and over and people aged 45-64 years.
Long COVID also possible after a mild case: interim research results More than 95% of the 1,741 participants in RIVM’s LongCOVID study, who reported long-term symptoms after COVID-19, had mild symptoms during the acute phase of the infection.